1.
Bioorg Med Chem Lett
; 27(20): 4678-4681, 2017 10 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28916339
RESUMO
According to the previously reported potent dual l-peptide PMI of p53-MDM2/MDMX interactions, a series of d-amino acid mutational PMI analogues, PMI-1-4, with enhanced proteolytic resistence and in vitro tumor cell inhibitory activities were reported, of which Liposome-PMI-1 showed a stronger inhibitory activity against the U87 cell lines than Nutlin-3. This d-amino acid mutation strategy may give a hand for enhancing the potential of peptide drugs.